From SCAI in Las Vegas: TAVR for The 90s
CardioSource Interventional News—Again, not a surprise: There are few data on nonagenarian patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Keita Yamasaki, MD, PhD, of the Karolinska University Hospital in Stockholm, reported on 22 consecutive patients between 90 and 96.8 years old with severe aortic stenosis who were not candidates for surgery and underwent TAVR. Follow-up ranged from 30 days to >3.5 years (570+/-378 days) with no deaths in the first 30 days (0/22) nor in the first year (0/15). Two deaths occurred subsequently: one after 398 days and the other 868 days post-procedure.
One patient experienced a stroke during the procedure and five required permanent pacing due to AV-block following the procedure. All patients were discharged to their homes.
This is a patient population that previously was largely untreated and, as a consequence, had high rates of morbidity and mortality when denied surgery. Now, TAVR may be a safe and effective treatment for severe aortic stenosis in nonagenarian patients.